[O-29] 一般演題口演セッション29
神経免疫３　E

[O-29-8] Pooled safety analysis from Phase 3 trials of satralizumab in neuromyelitis optica spectrum disorder

^○藤原 一男¹, Benjamin Greenberg², Jerome de Seze³, Edward Fox⁴, Albert Saiz⁵, 山村 隆⁶, Carole Marcillat⁷, Xiujing Kou⁷, Kristina Weber⁷, Brian G. Weinshenker⁸ (1.脳神経疾患研究所 多発性硬化症・視神経脊髄炎センター, 2.University of Texas Southwestern Medical Center, 3.Department of Neurology, Hôpital de Hautepierre INSERM, 4.Central Texas Neurology Consultants, 5.Service of Neurology, University of Barcelona, 6.National Institute of Neuroscience, National Center of Neurology and Psychiatry, 7.F. Hoffmann-La Roche Ltd, 8.Department of Neurology, Mayo Clinic)